Fibrogen INC Form 4 insider transactions

Juan Graham, CFO of FibroGen, disposed of shares to cover tax obligations arising from vesting restricted stock units.

CEO Wettig Thane of FibroGen, Inc. reports the disposition of 2,363 shares of common stock to cover tax obligations and an indirect holding of 1,000 shares through a spouse.

Christine Chung, SVP of China Operations at FibroGen, disposed of 17,395 shares of common stock to cover tax obligations upon vesting of restricted stock units.

CEO Wettig Thane of FibroGen, Inc. reports disposing of 20,840 shares of common stock to cover tax obligations arising from vesting restricted stock units.

CEO Wettig Thane of FibroGen, Inc. reports disposition of shares to cover tax obligations.

Deyaa Adib, Chief Medical Officer of FibroGen, reported acquiring 22,123 shares of common stock at $1.17 per share on June 12, 2024.

Juan Graham, CFO of FibroGen, Inc., reports the disposal of shares to cover tax obligations arising from the vesting of restricted stock units.

Christine Chung, SVP of China Operations at FibroGen, disposed of 19,289 shares of common stock on June 6, 2024, to cover tax obligations related to vesting restricted stock units.

CEO Wettig Thane of FibroGen, Inc. reports disposition of shares to cover tax obligations and discloses beneficial ownership.

Director James A. Schoeneck acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, according to a Form 4 filing.

Director Gerald Lema acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, according to a Form 4 filing.

Director Maykin Ho acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, according to a Form 4 filing.

Director Benjamin Cravatt acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, at an exercise price of $1.21.

Aoife Brennan, a director at FibroGen, acquired 70,000 stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Director Jeffrey Edwards acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024.

Director Suzanne Blaug acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, according to a Form 4 filing.

FibroGen CEO Wettig Thane reports the disposal of 20,840 shares to cover tax obligations and maintains beneficial ownership of 448,556 shares.

CEO Wettig Thane reports a transaction involving FibroGen stock, including shares withheld for tax obligations.

FibroGen's CEO, Thane Wettig, recently purchased 50,000 shares of the company's common stock at a price of $1.9094 per share.

Juan Graham, CFO of FibroGen, reports stock transactions including acquisitions and disposals to cover tax obligations.

FibroGen CEO Thane Wettig reports acquisition and disposal of company stock related to vesting of restricted stock units and PSU milestone grant.

Christine Chung, SVP of China Operations at FibroGen, reported the acquisition and disposal of company stock related to tax obligations and vesting of restricted stock units.